A Phase 1 interventional study of TPI-120 Pre-Filled Syringe 6 mg/0.6 mL in Healthy Volunteer, sponsored by Kashiv BioSciences, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-18.
Sponsored by Kashiv BioSciences, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The Goal of these study is to assess the comparative pharmacokinetics of Test Product (A): TPI-120 Injection 6 mg/0.6 mL solution in a single dose pre-filled autoinjector, manufactured by Kashiv Biosciences LLC, USA with Reference Product (B): TPI-120 Injection 6 mg/0.6 mL solution in a single dose pre-filled syringe manufactured by Kashiv Biosciences LLC, USA in healthy, adult human subjects and also to assess safety and tolerability of investigational product.
This study is an open label, randomized, two treatment, two sequence, two period, single dose crossover clinical trial designed to compare the pharmacokinetics, immunogenicity, and safety of Pegfilgrastim TPI 120 (Test) administered via pre filled syringe with auto injector and Fylnetra (Reference) administered via pre filled syringe. The study will be conducted in healthy adult human subjects under fasting conditions.
The study aims to enroll a sufficient number of participants to ensure that 180 healthy subjects complete dosing across both periods. Considering the required procedures and a washout period of at least 34 days between the dosing days of Period I and Period II, the total clinical study duration is approximately 51 days from the first check in. Subjects will be randomized into two treatment sequences and will receive a single subcutaneous dose of either the Test or Reference product in each study period.
The primary objective is to assess the pharmacokinetic (PK) comparability of the two Pegfilgrastim formulations by evaluating PK parameters including Cmax, AUCt, AUCi, Tmax, Kel, AUC%Extrap_obs, and tHalf. PK parameters will be calculated using Phoenix® WinNonlin® (Version 8.1.1 or higher) or SAS® (Version 9.4 or higher). Secondary objectives include assessment of safety and tolerability, as well as immunogenicity through anti drug antibody (ADA) evaluations.
Comprehensive safety assessments will be performed throughout the study. A complete physical examination will be conducted at screening and at the end of the study or early termination, while abbreviated physical examinations will occur during admission of each period, on Day 15 of Period I, and prior to discharge in each period. Clinical laboratory evaluations will include hematology, including absolute neutrophil count (ANC), coagulation (PT/INR), clinical chemistry, and urinalysis, performed at defined time points: screening, check in of Period 1, two days prior to Period 2 check in, Day 15 of Period I, and end of study or early termination.
A 12 lead ECG will be performed at screening, on Day 15 of Period I post dose, and at the end of the study or early termination. Safety screening also includes urine drug screens for drugs of abuse (amphetamine/methamphetamine, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, methadone, and phencyclidine) and alcohol breathalyzer testing at screening and prior to admission of each study period.
Subjects will be closely monitored for adverse events (AEs), serious adverse events (SAEs), changes in laboratory parameters, vital signs, and any clinically significant abnormalities. Immunogenicity evaluations will be performed at protocol specified time points to assess the presence of ADAs and potential neutralizing antibodies.
This study is designed to generate robust comparative PK, safety, and immunogenicity data to support the evaluation of biosimilar comparability between Pegfilgrastim TPI 120 and Fylnetra under fasting conditions in healthy adult subjects.
Kashiv BioSciences, LLC is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
First submitted before Kashiv BioSciences, LLC became part of Amneal Pharmaceuticals, Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention Group
Biological: TPI-120 Pre-Filled Syringe 6 mg/0.6 mL
Comparator Group
Biological: TPI-120 Pre-Filled Syringe 6 mg/0.6 mL
TPI-120 Pre-Filled Syringe 6 mg/0.6 mL with auto injector - Manufactured/supplied by: Kashiv Biosciences LLC, USA
Pharmacokinetic parameter
Cmax,
Time frame: Baseline to Day 15
Pharmacokinetic parameter
AUCt
Time frame: Time Frame: Baseline to Day 15
Pharmacokinetic parameter
AUC0-inf
Time frame: Time Frame: Baseline to Day 15
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in Oct 2025, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.